Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review
Open Access
- 17 March 2023
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (5) , 2051-2081
Abstract
Introduction Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and UC. Methods Two systematic literature reviews (SLRs) were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE®, Embase®, and Cochrane Library were searched for articles published between January 2011 and October 2021 and limited to non-interventional studies in English language. Congress and bibliographic searches were also conducted. Articles were screened by two independent researchers. Dose escalation patterns were described and summarized considering the regional regulatory label recommendation (in North America [NA] or outside of North America [ONA]). Results Among 3190 CD and 2116 UC articles identified in the Ovid searches, 100 CD and 54 UC studies were included in the SLR, with more studies conducted ONA. Most studies reported an initial maintenance dose pattern aligned with the lower starting dose per local regulatory label; however, several ONA studies (n = 13 out of 14) reported ustekinumab every 8 weeks as starting maintenance pattern in CD. In ONA studies, the median within-guideline escalation rates in CD and UC were 43% in ustekinumab (CD only), 33% and 32% for vedolizumab; 29% and 39% for adalimumab; and 14% and 10% for infliximab. Evidence regarding dose escalation patterns for tofacitinib, certolizumab pegol, and golimumab was limited. Some dose escalation patterns outside of label recommendations were observed including ustekinumab every 8 weeks to every 4 weeks and vedolizumab every 8 weeks to every 6 weeks. Conclusion Dose escalation strategies are widely documented in the literature. The reported dose escalation patterns and escalation rates vary by region and by CD and UC. Most escalation patterns reported were aligned with regulatory recommendations while some reported more diverse or aggressive dose escalation. Prospero Registration CRD42021289251.Keywords
Funding Information
- AbbVie
This publication has 194 references indexed in Scilit:
- Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease?European Journal of Gastroenterology & Hepatology, 2013
- Durability of Infliximab Dose Intensification in Crohn’s DiseaseDigestive Diseases and Sciences, 2011
- Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Predictors of efficacy, mucosal healing and dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from HungaryZeitschrift für Gastroenterologie, 2011
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing ResponseJournal of Clinical Gastroenterology, 2011
- Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart reviewJournal of Medical Economics, 2011
- Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAlimentary Pharmacology & Therapeutics, 2010
- The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximabAlimentary Pharmacology & Therapeutics, 2010
- The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative ColitisJournal of Occupational and Environmental Medicine, 2008